NeuroBo Pharmaceuticals | EFFECT:其他
NeuroBo Pharmaceuticals | 424B3:募資說明書
NeuroBo Pharmaceuticals | S-1:證券上市註冊聲明
NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals發布最新公司演示文稿
NeuroBo Pharmaceuticals | 4/A:持股變動聲明(修正)-股東 DONG-A ST CO., LTD
NeuroBo Pharmaceuticals | D:發行公告
NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals宣佈完成根據納斯達克規則在市場上定價的高達7000萬美元的並行私募和註冊直接發行
NeuroBo Pharmaceuticals | 4:持股變動聲明-股東 DONG-A ST CO., LTD
NeuroBo Pharmaceuticals | SC 13D/A:超過5%持股股東披露文件(修正)-Dong-A ST Co., Ltd.(53.5%)
NeuroBo Pharmaceuticals | 424B5:募資說明書
NeuroBo Pharmaceuticals | 8-K:簽訂證券購買協議
NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals的DA-1726在臨床前模型中表現出比Survodutide更優的減肥、保持瘦體重和降脂效果
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 Salsbury Michael
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 GROVES JASON L
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 KOVEN ANDREW I
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 Glickman Mark A
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 STRICKLAND D GORDON
NeuroBo Pharmaceuticals | 4:持股變動聲明-董事 Tursi James Patrick
NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals會議決議公告
NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals的DA-1241與索馬魯肽聯合治療可改善肝纖維化,並在臨床前MASH模型中與單獨使用任一治療方法相比顯示出附加的保肝作用
暫無數據